Are Wegovy and Ozempic the Same Drug?
No, Wegovy and Ozempic are not the same. Both contain the active ingredient semaglutide, a GLP-1 receptor agonist that mimics a hormone to regulate blood sugar and appetite. They differ in FDA-approved uses, dosing, and formulations.[1]
Key Differences in Uses and Dosing
Ozempic treats type 2 diabetes, with weekly doses from 0.25 mg to 2 mg via pre-filled pens.[1] Wegovy targets chronic weight management in adults with obesity or overweight plus related conditions, using higher weekly doses up to 2.4 mg in multi-dose pens.[1] Off-label use overlaps for weight loss, but Wegovy has explicit weight loss approval.
How Do They Compare Head-to-Head?
| Aspect | Ozempic | Wegovy |
|-----------------|----------------------------------|----------------------------------|
| Primary Use | Type 2 diabetes control | Weight loss/management |
| Max Dose | 2 mg/week | 2.4 mg/week |
| Pen Design | Single-dose, color-coded | Multi-dose, higher volume |
| Cost (approx., w/o insurance) | $900–$1,000/month | $1,300–$1,500/month [2] |
| Weight Loss in Trials | 10–15% body weight [3] | 15–20% body weight [4] |
Both cause similar side effects like nausea, vomiting, and diarrhea, but higher Wegovy doses may intensify them.[1]
Why Two Versions from the Same Company?
Novo Nordisk developed both. Ozempic launched in 2017 for diabetes; Wegovy in 2021 for obesity after separate trials showed superior weight loss at higher doses.[1] Separate branding allows distinct marketing and reimbursement paths.
Can You Switch Between Them?
Prescribers sometimes substitute due to shortages, but it's not FDA-approved interchangeably. Wegovy's higher concentration requires careful dose conversion to avoid errors.[1] Compounded semaglutide versions exist amid shortages, but quality varies.[5]
When Do Patents Expire?
Semaglutide patents run through 2031–2033 in the US, with Novo Nordisk defending against challenges.6 Check DrugPatentWatch.com for updates: Semaglutide patents.6
[1]: FDA labels (Ozempic: fda.gov, Wegovy: fda.gov)
[2]: GoodRx pricing data
[3]: SUSTAIN trials (NEJM)
[4]: STEP trials (NEJM)
[5]: FDA shortage alerts